Nascent Biotech, Inc. (NBIO)

Market Cap	51.85K -99.8%
Revenue (ttm)	n/a
Net Income	-1.92M
EPS	-0.01
Shares Out	172.84M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	15,000
Average Volume	27,127
Open	0.0005
Previous Close	0.0003
Day's Range	0.0003 - 0.0005
52-Week Range	0.0000 - 0.1345
Beta	2.27
RSI	47.52
Earnings Date	Feb 13, 2026

About Nascent Biotech

Nascent Biotech, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer. The company is developing MultiPharm, a proprietary technology platform for cancer therapy, as well as diabetes, autoimmunity, and transplantation. In addition, it develops CLNH5. Na...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Sean Carrick
• Country: United States
• Stock Exchange: OTCMKTS
• Ticker Symbol: NBIO